| scholarly article | Q13442814 |
| P356 | DOI | 10.1089/THY.2013.0621 |
| P8608 | Fatcat ID | release_c27dfcyh5bhtvnct75ns2g567y |
| P932 | PMC publication ID | 4106376 |
| P698 | PubMed publication ID | 24724719 |
| P2093 | author name string | James Reynolds | |
| Shivaani Kummar | |||
| Francesco S Celi | |||
| Ravi A Madan | |||
| Andrea B Apolo | |||
| Jaydira del Rivero | |||
| Sahzene Yavuz | |||
| Thomas Shawker | |||
| P2860 | cites work | Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma | Q27003439 |
| Scintigraphy with 99mTc-pertechnetate in the evaluation of functional thyroidal autonomy | Q33776929 | ||
| The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma | Q34543752 | ||
| Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity | Q36804701 | ||
| The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation | Q36858013 | ||
| Unusual case of amiodarone-induced thyrotoxicosis: "illicit" use of a technetium scan to diagnose a transiently toxic thyroid nodule | Q36899425 | ||
| Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target | Q37254710 | ||
| Tyrosine kinase inhibitors and modifications of thyroid function tests: a review | Q37356708 | ||
| Conditions and drugs interfering with thyroxine absorption | Q37639664 | ||
| Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma | Q37926019 | ||
| Subacute, silent, and postpartum thyroiditis | Q37996539 | ||
| Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis | Q38080563 | ||
| Thyroid dysfunction as an unintended side effect of anticancer drugs. | Q38113279 | ||
| Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients | Q38375556 | ||
| Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia | Q42867411 | ||
| Sorafenib-Induced Destructive Thyroiditis | Q42913770 | ||
| Sunitinib-Induced Thyrotoxicosis Followed by Persistent Hypothyroidism with Shrinkage of Thyroid Volume | Q42918821 | ||
| Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma | Q42928425 | ||
| Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination | Q43059498 | ||
| Sunitinib induces hypothyroidism with a markedly reduced vascularity | Q43148186 | ||
| Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? | Q43167326 | ||
| Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation | Q43242171 | ||
| Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma | Q44955867 | ||
| Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies | Q46481053 | ||
| The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis | Q46500038 | ||
| Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. | Q46660395 | ||
| Imatinib induces hypothyroidism in patients receiving levothyroxine | Q46731246 | ||
| Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib | Q46930597 | ||
| Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function | Q47368293 | ||
| Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma | Q47713907 | ||
| Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport | Q48819442 | ||
| Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. | Q50896204 | ||
| Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. | Q51017184 | ||
| Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. | Q55042679 | ||
| A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake | Q61794209 | ||
| Color Doppler ultrasonography in patients with subacute thyroiditis | Q73383324 | ||
| Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report | Q80831056 | ||
| Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? | Q84304427 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1223-1231 | |
| P577 | publication date | 2014-06-05 | |
| P1433 | published in | Thyroid | Q15709940 |
| P1476 | title | Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma | |
| P478 | volume | 24 |
| Q38625034 | Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer |
| Q97519474 | Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial |
| Q38880117 | KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. |
| Q38718947 | Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib |
| Q38534167 | Targeting the VEGF pathway in metastatic bladder cancer |
| Q38778384 | The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells |
| Q26796404 | The treatment landscape in thyroid cancer: a focus on cabozantinib |
Search more.